Troy Cox

CIK: 0001696923

Transaction Breakdown

Open Market Buys (P)1 (12.5%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (87.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

MPLT

MapLight Therapeutics, Inc.

Director

LAB

STANDARD BIOTOOLS INC.

Director

SOPH

SOPHiA GENETICS SA

Director

ZYME

Zymeworks Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

MPLT
MapLight Therapeutics, Inc.
Jul 28, 2026
Purchase(P)
Indirect
15.6K shares at avg. $9.52$149K
MPLT
MapLight Therapeutics, Inc.
Jun 23, 2026
Award(A)
Direct
7.9K shares-
LAB
STANDARD BIOTOOLS INC.
Jun 18, 2026
Award(A)
Direct
99.1K shares-
SOPH
SOPHiA GENETICS SA
Jun 18, 2026
Award(A)
Direct
19.7K shares at avg. $5.46$108K
LAB
STANDARD BIOTOOLS INC.
Feb 26, 2026
Award(A)
Direct
57.3K shares at avg. $1.17$67K
LAB
STANDARD BIOTOOLS INC.
Jun 20, 2025
Award(A)
Direct
94.6K shares-
LAB
STANDARD BIOTOOLS INC.
Feb 28, 2025
Award(A)
Direct
62.9K shares at avg. $1.06$67K
ZYME
Zymeworks Inc.
Dec 10, 2024
Award(A)
Stock Option (Right to Buy)
Direct
31K shares-

		Type	Shares	Price		Ownership
Jul 28, 2026	MPLT MapLight Therapeutics, Inc.	Purchase(P)	15,620	$9.52	$148,702	Indirect
Jun 23, 2026	MPLT MapLight Therapeutics, Inc.	Award(A)	7,864	-	$0	Direct
Jun 18, 2026	LAB STANDARD BIOTOOLS INC.	Award(A)	99,116	-	$0	Direct
Jun 18, 2026	SOPH SOPHiA GENETICS SA	Award(A)	19,724	$5.46	$107,693	Direct
Feb 26, 2026	LAB STANDARD BIOTOOLS INC.	Award(A)	57,264	$1.17	$66,999	Direct
Jun 20, 2025	LAB STANDARD BIOTOOLS INC.	Award(A)	94,592	-	-	Direct
Feb 28, 2025	LAB STANDARD BIOTOOLS INC.	Award(A)	62,910	$1.06	$66,999	Direct
Dec 10, 2024	ZYME Zymeworks Inc.	Award(A) Stock Option (Right to Buy)	31,000	-	-	Direct

1-8 of 8 transactions

About Cox Troy

Cox Troy (SEC CIK 0001696923) files insider reports with the SEC as Director of MapLight Therapeutics, Inc. (MPLT), Director of STANDARD BIOTOOLS INC. (LAB) and Director of SOPHiA GENETICS SA (SOPH). Signal8 also holds filings tied to 1 other company.

Signal8 holds 11 ownership filings by Cox Troy (2 Form 3, 9 Form 4), filed between Dec 12, 2024 and Jul 28, 2026. Those filings report 8 transactions, from Dec 10, 2024 to Jul 28, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cox Troy's filings is in REDWOOD CITY, CA.

Recent filings by Cox Troy

Jul 28, 2026: Open-market purchase of MPLT shares (Form 4, code P).
Jun 23, 2026: Grant or award of MPLT shares (Form 4, code A).
Jun 18, 2026: Grant or award of LAB shares (Form 4, code A).
Jun 18, 2026: Grant or award of SOPH shares (Form 4, code A).
Feb 26, 2026: Grant or award of LAB shares (Form 4, code A).

Other insiders filing for MapLight Therapeutics, Inc. (MPLT)

Kreitzer Anatol, Chief Discovery Officer
GILLIS JONATHAN, CAO and Interim CFO
Lillie James Woodruff, Chief Scientific Officer
Hanson Kristopher, General Counsel
Foff Erin Pennock, Chief Medical Officer
Kroeger Christopher A., Chief Executive Officer

How to read Form 4 transaction codes